All In Biotech

Drug Trial Radar · NCT06111235

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

367

Actual

Start

Dec 14, 2023

Primary completion

Nov 2026

Study completion Feb 2029

Sponsor

Lead sponsor
CG Oncology, Inc.Industry
Sponsor type
Industry
First posted
Nov 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.

Conditions

  • Non Muscle Invasive Bladder Cancer
  • Urologic Cancer
  • Bladder Cancer
  • Urothelial Carcinoma

Interventions

  • Cretostimogene GrenadenorepvecDrug

    Engineered Oncolytic Adenovirus

  • n-dodecyl-B-D-maltosideOther

    Transduction-enhancing agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS)Time frame: 29 months

Locations

95 sites in 2 countries. Site status is shown where the registry gives one.

  • Urology Centers of Alabama PC

    Homewood, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Arizona Institute of Urology PLLC

    Tucson, Arizona

  • Arkansas Urology PA

    Little Rock, Arkansas

  • Michael G. Oefelein MD Clinical Trials

    Bakersfield, California

  • USC/Keck Department of Urology

    Los Angeles, California

  • Tower Urology

    Los Angeles, California

  • Sun Kim Urology

    Orange, California

  • University of California Irvine Medical Center (UCIMC)

    Orange, California

  • University of California Davis Cancer Center

    Sacramento, California

  • Stanford University School of Medicine

    Stanford, California

  • Colorado Clinical Research

    Aurora, Colorado

  • Urology Associates, PC

    Lone Tree, Colorado

  • Hartford HealthCare Medical Group

    Hartford, Connecticut

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Advanced Urology Institute

    Daytona Beach, Florida

  • Mayo Clinic Cancer Center

    Jacksonville, Florida

  • Lakeland Regional Health

    Lakeland, Florida

  • Advanced Urology Institute, LLC

    Largo, Florida

  • University of Miami

    Miami, Florida

  • Emory Winship Cancer Center

    Atlanta, Georgia

  • Velocity Clinical Research- Savanah Urological Associates

    Savannah, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • UroPartners LLC

    Glenview, Illinois

  • Duly Health and Care

    Lisle, Illinois

  • Urology of Indiana, LLC

    Carmel, Indiana

  • Urology of Indiana

    Greenwood, Indiana

  • Urology Center of Iowa Research

    West Des Moines, Iowa

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Wichita Urology Group

    Wichita, Kansas

  • First Urology, PSC

    Louisville, Kentucky

  • Southern Urology

    Lafayette, Louisiana

  • Regional Urology, LLC

    Shreveport, Louisiana

  • Chesapeake Urology Associates, LLC

    Baltimore, Maryland

  • Johns Hopkins Hospital Green Spring Station

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Cancer Center at Beth Israel Deaconess Medical Center - Research

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

Showing 40 of 95 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.